Related Experiment Video

Updated: May 28, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Molecular targeted therapy in melanoma: a way to reverse resistance to conventional drugs

Francesca Maira1, Alessia Catania, Saverio Candido

  • 1Department of Biomedical Sciences, Section of General Pathology & Oncology, University of Catania, Italy.

Current Drug Delivery
|October 26, 2011
PubMed

Insights

Cutaneous melanoma, a dangerous skin cancer, often relapses after treatment. Emerging targeted therapies show promise in overcoming drug resistance and improving patient outcomes.

Area of Science:

  • Oncology
  • Dermatology
  • Molecular Biology

Background:

  • Cutaneous melanoma is the most aggressive form of skin cancer.
  • Standard treatments include surgery, chemotherapy, and immunotherapy.
  • Adjuvant therapy often leads to patient relapse.

Purpose of the Study:

  • To review environmental factors and molecular events in melanoma pathogenesis.
  • To disclose mechanisms of drug resistance in melanoma.
  • To highlight emerging targeted therapies and clinical trials for melanoma.

Main Methods:

  • Literature review of environmental factors and molecular pathways in melanoma.
  • Analysis of mechanisms contributing to drug resistance.
  • Summary of current clinical trials for targeted melanoma therapies.

Main Results:

  • Key molecular pathways driving melanoma pathogenesis have been identified.
  • Understanding these pathways is crucial for developing new treatments.
  • Targeted therapies offer potential to overcome resistance to conventional treatments.

Conclusions:

  • Emerging targeted therapies hold significant promise for managing melanoma.
  • Further research into molecular mechanisms and clinical trials is essential.
  • Personalized treatment strategies are key to improving melanoma patient survival.

More Related Videos

A 3D Organotypic Melanoma Spheroid Skin Model08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

A Melanoma Patient-Derived Xenograft Model07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.